Nkarta, Inc. (NKTX)
2.76
+0.06
(+2.22%)
USD |
NASDAQ |
Sep 02, 16:00
2.76
0.00 (0.00%)
After-Hours: 17:49
Nkarta Research and Development Expense (Annual) : 81.24M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 81.24M |
| December 31, 2024 | 87.59M |
| December 31, 2023 | 90.90M |
| December 31, 2022 | 88.26M |
| Date | Value |
|---|---|
| December 31, 2021 | 61.66M |
| December 31, 2020 | 35.43M |
| December 31, 2019 | 16.82M |
| December 31, 2018 | 4.069M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| Theriva Biologics, Inc. | 8.604M |
| Unicycive Therapeutics, Inc. | 9.121M |
| OnKure Therapeutics, Inc. | 47.81M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |